These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 3718810)

  • 1. A comparison of the pharmacokinetics of propranolol in obese and normal volunteers.
    Bowman SL; Hudson SA; Simpson G; Munro JF; Clements JA
    Br J Clin Pharmacol; 1986 May; 21(5):529-32. PubMed ID: 3718810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of propranolol during pregnancy.
    O'Hare MF; Kinney CD; Murnaghan GA; McDevitt DG
    Eur J Clin Pharmacol; 1984; 27(5):583-7. PubMed ID: 6519163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of ageing on the hepatic clearance of propranolol.
    Castleden CM; George CF
    Br J Clin Pharmacol; 1979 Jan; 7(1):49-54. PubMed ID: 760742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions of phenobarbital with propranolol in the dog. 2. Bioavailability, metabolism and pharmacokinetics.
    Vu VT; Bai SA; Abramson FP
    J Pharmacol Exp Ther; 1983 Jan; 224(1):55-61. PubMed ID: 6848749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No stereoselective first-pass hepatic extraction of propranolol.
    Jackman GP; McLean AJ; Jennings GL; Bobik A
    Clin Pharmacol Ther; 1981 Sep; 30(3):291-6. PubMed ID: 7273593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability of propranolol in the dog.
    Tse FL; Sanders TM; Reo JP
    Arch Int Pharmacodyn Ther; 1980 Dec; 248(2):180-9. PubMed ID: 7224706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis.
    Olanoff LS; Walle T; Cowart TD; Walle UK; Oexmann MJ; Conradi EC
    Clin Pharmacol Ther; 1986 Oct; 40(4):408-14. PubMed ID: 3757404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereoselective clearance and distribution of intravenous propranolol.
    Olanoff LS; Walle T; Walle UK; Cowart TD; Gaffney TE
    Clin Pharmacol Ther; 1984 Jun; 35(6):755-61. PubMed ID: 6734027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics and cardiac effects of propranolol in humans.
    Ochs HR; Grube E; Greenblatt DJ; Knüchel M; Bodem G
    Klin Wochenschr; 1982 May; 60(10):521-5. PubMed ID: 7098380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers.
    Cheymol G; Poirier JM; Barre J; Pradalier A; Dry J
    J Clin Pharmacol; 1987 Nov; 27(11):874-9. PubMed ID: 3429695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of the absorption and removal of propranolol in hypertensive patients during therapy.
    Chidsey CA; Morselli P; Bianchetti G; Morganti A; Leonetti G; Zanchetti A
    Circulation; 1975 Aug; 52(2):313-8. PubMed ID: 1149212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin.
    Greenblatt DJ; Abernethy DR; Boxenbaum HG; Matlis R; Ochs HR; Harmatz JS; Shader RI
    Arthritis Rheum; 1986 Aug; 29(8):971-80. PubMed ID: 3741521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of experimental renal failure on the disposition kinetics of l-propranolol in rats.
    Terao N; Shen DD
    J Pharmacol Exp Ther; 1983 Nov; 227(2):295-301. PubMed ID: 6631714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of diltiazem after intravenous and oral administration.
    Hermann P; Rodger SD; Remones G; Thenot JP; London DR; Morselli PL
    Eur J Clin Pharmacol; 1983; 24(3):349-52. PubMed ID: 6861848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent disposition of oral propranolol in normal subjects.
    Mackichan JJ; Pyszczynski DR; Jusko WJ
    Biopharm Drug Dispos; 1980; 1(4):159-66. PubMed ID: 7448344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of physical exercise on the pharmacokinetics of propranolol.
    Arends BG; Böhm RO; van Kemenade JE; Rahn KH; van Baak MA
    Eur J Clin Pharmacol; 1986; 31(3):375-7. PubMed ID: 3792439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics of dexfenfluramine in obese and non-obese subjects.
    Cheymol G; Weissenburger J; Poirier JM; Gellee C
    Br J Clin Pharmacol; 1995 Jun; 39(6):684-7. PubMed ID: 7654489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of propranolol.
    Routledge PA; Shand DG
    Clin Pharmacokinet; 1979; 4(2):73-90. PubMed ID: 378502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of food on the intravenous and oral dose kinetics of propranolol in the dog.
    Bai SA; Walle UK; Walle T
    J Pharmacokinet Biopharm; 1985 Jun; 13(3):229-41. PubMed ID: 4087163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects.
    Wójcicki J; Jaroszynska M; Droździk M; Pawlik A; Gawrońska-Szklarz B; Sterna R
    Biopharm Drug Dispos; 2003 Jul; 24(5):211-8. PubMed ID: 12784321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.